Advertisement

Development and Testing of a Decision Aid for Unaffected Women with a BRCA1 or BRCA2 Mutation

  • Terri JabaleyEmail author
  • Meghan L. Underhill-Blazey
  • Donna L. Berry
Article

Abstract

For women who are unaffected carriers of a pathogenic BRCA mutation, cancer risk management requires ongoing education, counseling, and support from an interdisciplinary team of medical specialists, genetic counselors, and nurses specializing in genomics. The purpose of this study was to develop and pilot test an educational, patient-focused decision aid to facilitate shared decision making. A steering committee developed the prototype aid after an extensive review of the literature. The aid was designed at the ninth-grade reading level, to be consistent with internationally accepted clinical guidelines and inclusive of all risk management options and psychosocial issues important to cancer risk management decision making. The aid was tested with 23 participants: eight experts and 15 end users. Eleven survey items were asked related to organization, clarity, usefulness, comprehensiveness, ease of understanding, and relevance to the cancer risk management decision-making process. Mean scores were 3 or higher on Likert scales of 1–4 (high) for each of the 11 items. Two open-ended questions elicited general comments and suggestions for additions, deletions, or revisions to the decision aid. The steering committee made final revisions to the aid based on participant feedback and committee consensus.

Keywords

BRCA 1/2 Genetics/genomics Hereditary breast and ovarian cancer syndrome Decision aid Educational material 

Notes

Funding Information

This study was funded in part by the Pi Epsilon chapter of Sigma Honor Society for Nursing.

Compliance with Ethical Standards

Approvals were obtained from the Committee for the Protection of Human Participants in Research at Emmanuel College, the executive director of FORCE, and the regional FORCE support group chairperson. Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Chewning B, Bylund CL, Shah B, Arora NK, Gueguen JA, Makoul G (2012) Patient preferences for shared decisions: a systematic review. Patient Educ Couns 86(1):9–18.  https://doi.org/10.1016/j.pec.2011.02.004 CrossRefPubMedGoogle Scholar
  2. 2.
    Coulter A, Stilwell D, Kryworuchko J, Mullen PD, Ng CJ, van der Weijden T (2013) A systematic development process for patient decision aids. BMC Med Inform Decis Mak 13(Suppl 2):S2.  https://doi.org/10.1186/1472-6947-13-S2-S2 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Crotser CB, Dickerson SS (2010) Women receiving news of a family BRCA1/2 mutation: messages of fear and empowerment. J Nurs Scholarsh 42(4):367–378.  https://doi.org/10.1111/j.1547-5069.2010.01366.x CrossRefPubMedGoogle Scholar
  4. 4.
    Culver JO, MacDonald DJ, Thornton AA, Sand SR, Grant M, Bowen DJ, Burke H, Garcia N, Metcalfe KA, Weitzel JN (2011) Development and evaluation of a decision aid for BRCA carriers with breast cancer. J Genet Couns 20(3):294–307CrossRefGoogle Scholar
  5. 5.
    Empowered, Facing our Risk of Cancer. 2018. What is a previvor? http://www.facingourrisk.org/understanding-brca-and-hboc/publications/newsletter/archives/2009winter/what-is-previvor.php. Accessed October 25, 2018.
  6. 6.
    Evans DG, Gaarenstroom KN, Stirling D, Shenton A, Maehle L, Dørum A, Steel M, Lalloo F, Apold J, Porteous ME (2009) Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J Med Genet 46(9):593–597CrossRefGoogle Scholar
  7. 7.
    Heijer M, Seynaeve C, Vanheusden K, Timman R, Duivenvoorden HJ, Tilanus-Linthorst M, Menke-Pluijmers MBE, Tibben A (2013) Long-term psychological distress in women at risk for hereditary breast cancer adhering to regular surveillance: a risk profile. Psycho-Oncology 22(3):598–604.  https://doi.org/10.1002/pon.3039 CrossRefGoogle Scholar
  8. 8.
    Institute, Ottawa Hospital Research. 2015. Ottawa decision support framework. https://decisionaid.ohri.ca/odsf.html. Accessed October 24, 2018
  9. 9.
    Jabaley T, Mawn BE (2015) Cancer risk management decision making for BRCA+ women. West J Nurs Res 37(1):66–84.  https://doi.org/10.1177/0193945913519870 CrossRefGoogle Scholar
  10. 10.
    Joseph-Williams N, Newcombe R, Politi M, Durand MA, Sivell S, Stacey D, Connor A et al (2014) Toward minimum standards for certifying patient decision aids: a modified Delphi consensus process. Med Decis Making 34(6):699–710.  https://doi.org/10.1177/0272989x13501721 CrossRefPubMedGoogle Scholar
  11. 11.
    Kaufman EM, Peshkin BN, Lawrence WF, Shelby R, Isaacs C, Brown K, Rispoli J, O'neill S, Hurley K, DeMarco T (2003) Development of an interactive decision aid for female BRCA1/BRCA2 carriers. J Genet Couns 12(2):109–129CrossRefGoogle Scholar
  12. 12.
    Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, Goldgar DE, Terry MB, Rookus MA, Easton DF, Antoniou AC, and the BRCA1 and BRCA2 Cohort Consortium, McGuffog L, Evans DG, Barrowdale D, Frost D, Adlard J, Ong KR, Izatt L, Tischkowitz M, Eeles R, Davidson R, Hodgson S, Ellis S, Nogues C, Lasset C, Stoppa-Lyonnet D, Fricker JP, Faivre L, Berthet P, Hooning MJ, van der Kolk LE, Kets CM, Adank MA, John EM, Chung WK, Andrulis IL, Southey M, Daly MB, Buys SS, Osorio A, Engel C, Kast K, Schmutzler RK, Caldes T, Jakubowska A, Simard J, Friedlander ML, McLachlan SA, Machackova E, Foretova L, Tan YY, Singer CF, Olah E, Gerdes AM, Arver B, Olsson H (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402–2416.  https://doi.org/10.1001/jama.2017.7112. CrossRefPubMedGoogle Scholar
  13. 13.
    Kurian AW, Munoz DF, Rust P, Schackmann EA, Smith M, Clarke L, Mills MA, Plevritis SK (2012) Online tool to guide decisions for BRCA1/2 mutation carriers. J Clin Oncol 30(5):497–506.  https://doi.org/10.1200/JCO.2011.38.6060 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Llort G, Chirivella I, Morales R, Serrano R, Beatriz Sanchez A, Teulé A, Lastra E, Brunet J, Balmaña J, Graña B (2015) SEOM clinical guidelines in hereditary breast and ovarian cancer. Clin Transl Oncol 17(12):956–961CrossRefGoogle Scholar
  15. 15.
    Metcalfe KA, Dennis CL, Poll A, Armel S, Demsky R, Carlsson L, Nanda S, Kiss A, Narod SA (2017) Effect of decision aid for breast cancer prevention on decisional conflict in women with a BRCA1 or BRCA2 mutation: a multisite, randomized, controlled trial. Genet Med 19(3):330–336.  https://doi.org/10.1038/gim.2016.108 CrossRefPubMedGoogle Scholar
  16. 16.
    NCCN. 2018. Genetic/familial high-risk assessment: breast and ovarian version 2.2019. https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Accessed October 24, 2018
  17. 17.
    Osaka W, Nakayama K (2017) Effect of a decision aid with patient narratives in reducing decisional conflict in choice for surgery among early-stage breast cancer patients: a three-arm randomized controlled trial. Patient Educ Couns 100(3):550–562.  https://doi.org/10.1016/j.pec.2016.09.011
  18. 18.
    Petrucelli, Nancie, Mary B Daly, and Tuya Pal. 2016. BRCA1-and BRCA2-associated hereditary breast and ovarian cancer.Google Scholar
  19. 19.
    Promotion, Office of Disease Prevention and Health. 2018. Genomics. https://www.healthypeople.gov/2020/topics-objectives/topic/genomics. Accessed October 24, 2018.
  20. 20.
    Schackmann EA, Munoz DF, Mills MA, Plevritis SK, Kurian AW (2013) Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers. Familial Cancer 12(1):65–73CrossRefGoogle Scholar
  21. 21.
    Scherr CL, Feuston JL, Nixon DM, Cohen SA (2018) A two-phase approach to developing SNAP: an iPhone application to support appointment scheduling and management for women with a BRCA mutation. J Genet Couns 27(2):439–445.  https://doi.org/10.1007/s10897-018-0222-z CrossRefPubMedGoogle Scholar
  22. 22.
    Stacey D, Légaré F, Lewis K, Barry MJ, Bennett CL, Eden KB, Holmes-Rovner M et al (2017) Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev (4).  https://doi.org/10.1002/14651858.CD001431.pub5
  23. 23.
    Stan DL, Shuster LT, Wick MJ, Swanson CL, Pruthi S, Bakkum-Gamez JN (2013) Challenging and complex decisions in the management of the BRCA mutation carrier. J Women’s Health 22(10):825–834.  https://doi.org/10.1089/jwh.2013.4407 CrossRefGoogle Scholar
  24. 24.
    Tiller K, Meiser B, Reeson E, Tucker M, Andrews L, Gaff C, Kirk J, Phillips KA, Friedlander M (2003) A decision aid for women at increased risk for ovarian cancer. Int J Gynecol Cancer 13(1):15–22CrossRefGoogle Scholar
  25. 25.
    Wellings E, Vassiliades L, Abdalla R (2016) Breast cancer screening for high-risk patients of different ages and risk—which modality is most effective? Cureus 8(12):e945.  https://doi.org/10.7759/cureus.945. CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© American Association for Cancer Education 2019

Authors and Affiliations

  • Terri Jabaley
    • 1
    Email author
  • Meghan L. Underhill-Blazey
    • 2
  • Donna L. Berry
    • 1
  1. 1.The Phyllis F. Cantor Center for Research in Nursing and Patient Care ServicesDana Farber Cancer InstituteBostonUSA
  2. 2.The Phyllis F. Cantor Center for Research in Nursing and Patient Care Services, Cancer Genetics and Prevention ProgramDana-Farber Cancer InstituteBostonUSA

Personalised recommendations